Comedian Tom Segura recently appeared on the “Joe Rogan Experience” podcast. During the 3-hour conversation, Rogan and Segura talked about several topics like comedy, politics, and health.
At one point during the episode, Segura discussed his personal experience with the experimental drug SLU-PP-332. He referenced animal studies suggesting the compound could reduce fat gain, increase lean mass, and improve metabolic function –all without changes in appetite or activity.
SLU-PP-332 became a popular agent for weight loss among the wider public. According to this study, tests made on obese animals showed a decrease of up to 12% in fat production. The research also found a significant decrease in fat concentrations in the liver, as well as lowered insulin production.
Segura described the experimental drug as doing a workout without really moving. According to him, he noticed a significant decrease in bodyweight fat, activity, and even sexual drive.
Notably, the comedian lost a considerable amount of weight over the past few years. While many of his fans suspected that he was using Ozempic to help with the weight loss, Segura claims that it was SLU-PP-332 that really helped him in that journey.
Despite being in the same family, SLU-PP-332 is not “really” a peptide. It is actually a synthetic small-molecule hydrazide, not a chain of amino acids. It acts as a pan‑ERR agonist (estrogen‑related receptor activator). ERRs are nuclear receptors that regulate energy metabolism. By activating them, SLU‑PP‑332 mimics some of the cellular effects of exercise.
Due to the similar health benefits, online forums and other places in the media will usually refer to SLU-PP-332 as a peptide, despite these key differences.
So much so that the compound was excluded from the FDA’s 503A compounding list when a board of regulators recently approved a slate of true peptides for pharmacy use. While substances like BPC‑157, thymosin beta‑4 fragments, and other amino-acid-based peptides were granted eligibility, SLU‑PP‑332 remains outside of regulatory developments.